Quality of life in Polish patients with long-lasting Parkinson's disease
- PMID: 15197705
- DOI: 10.1002/mds.10698
Quality of life in Polish patients with long-lasting Parkinson's disease
Abstract
The objective of this study was to evaluate possible relationships between quality of life (QoL) of Polish patients with long-lasting Parkinson's disease and various demographic and clinical factors. The study comprised 141 patients of Movement Disorders outpatient clinics in Warsaw and Gdansk with at least 5 years of the disease duration. Mean age of patients was 68.09 +/- 8.51 years, mean duration of disease was 11.87 +/- 5.14 years. To assess the quality of life, the Parkinson's Disease Questionnaire (PDQ-39) was used. Additional questions concerned duration of disease, initial and current treatment and expenses associated with therapy. Self-perceived symptoms of depression were in our study the most important factor determining QoL. Duration of the disease and expenses related to the treatment also have a significant impact on the QoL. Patient's age and presence of dyskinesia seem to be irrelevant to the quality of life.
Copyright 2003 Movement Disorder Society
Similar articles
-
Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life.Mov Disord. 2005 May;20(5):616-9. doi: 10.1002/mds.20393. Mov Disord. 2005. PMID: 15719417
-
Depressive symptoms impacting on health-related quality of life in early Parkinson's disease: results from Chinese L-dopa exposed cohort.Clin Neurol Neurosurg. 2009 Nov;111(9):733-7. doi: 10.1016/j.clineuro.2009.07.001. Epub 2009 Aug 8. Clin Neurol Neurosurg. 2009. PMID: 19665835 Clinical Trial.
-
Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life.Parkinsonism Relat Disord. 2010 Mar;16(3):218-21. doi: 10.1016/j.parkreldis.2009.07.015. Epub 2009 Sep 16. Parkinsonism Relat Disord. 2010. PMID: 19762271 Clinical Trial.
-
Pharmacologic management of Parkinson's disease in long-term care residents: maintaining functionality to improve quality of life.Director. 2007 Spring;15(2):20-9. Director. 2007. PMID: 19343903 Review. No abstract available.
-
Pharmacology of Parkinson's disease.Neurol Clin. 1984 Aug;2(3):461-72. Neurol Clin. 1984. PMID: 6152482 Review.
Cited by
-
The impact of levodopa therapy-induced complications on quality of life in Parkinson's disease patients in Singapore.Sci Rep. 2019 Jun 25;9(1):9248. doi: 10.1038/s41598-019-45110-5. Sci Rep. 2019. PMID: 31239456 Free PMC article. Clinical Trial.
-
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?BMC Med. 2013 Mar 20;11:76. doi: 10.1186/1741-7015-11-76. BMC Med. 2013. PMID: 23514355 Free PMC article. Review.
-
Treatment of Parkinson's disease: a survey of patients and neurologists.Clin Drug Investig. 2007;27(3):207-18. doi: 10.2165/00044011-200727030-00004. Clin Drug Investig. 2007. PMID: 17305415
-
Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort study.J Neurol. 2010 Apr;257(4):638-45. doi: 10.1007/s00415-009-5389-7. Epub 2009 Nov 28. J Neurol. 2010. PMID: 19946784
-
The influence of depression, level of functioning in everyday life, and illness acceptance on quality of life in patients with Parkinson's disease: a preliminary study.Neuropsychiatr Dis Treat. 2017 Mar 21;13:881-887. doi: 10.2147/NDT.S132757. eCollection 2017. Neuropsychiatr Dis Treat. 2017. PMID: 28356744 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical